Automate Your Wheel Strategy on YMAB
With Tiblio's Option Bot, you can configure your own wheel strategy including YMAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol YMAB
- Rev/Share 1.9656
- Book/Share 1.9833
- PB 4.2908
- Debt/Equity 0.0067
- CurrentRatio 4.7712
- ROIC -0.3242
- MktCap 385467258.0
- FreeCF/Share -0.4273
- PFCF -19.9983
- PE -13.5954
- Debt/Assets 0.0054
- DivYield 0
- ROE -0.3059
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | YMAB | BofA Securities | Neutral | Underperform | -- | $3 | April 22, 2025 |
| Initiation | YMAB | Cantor Fitzgerald | -- | Overweight | -- | $20 | Aug. 16, 2024 |
News
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Published: August 05, 2025 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE , Aug. 5, 2025 /PRNewswire/ -- The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read More
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
YmAbs Therapeutics (YMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
Published: May 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of GD2-SADA in recurrent or refractory metastatic solid tumors known to express GD2 in a trial in progress poster at the Advances in Neuroblastoma Research Meeting (“ANR”) being held on May 25-28, 2025 in Washington, D.C.
Read More
Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Courtney Dugan - Vice President, Head of Investor Relations Michael Rossi - President and Chief Executive Officer Doug Gentilcore - DANYELZA Business Unit Head Peter Pfreundschuh - Chief Financial Officer Conference Call Participants Nicole Germino - Truist Securities Mike Ulz - Morgan Stanley Justin Walsh - Jones Trading Li Watsek - Cantor John Newman - Canaccord Genuity Jeff Jones - Oppenheimer Bill Maughan - Clear Street David Nierengarten - Wedbush Kemp Dolliver - Brookline Capital Markets Chiara Montironi - Van Lanschot Kempen …
Read More
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that naxitamab-gqgk (DANYELZA®) is recommended by the National Comprehensive Cancer Network® (“NCCN”) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a NCCN Category 2A treatment option for high-risk neuroblastoma.
Read More
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the first quarter 2025 before the market open on Tuesday, May 13, 2025.
Read More
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
Published: April 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of Cancer Research (AACR) Annual Meeting being held on April 25-30, 2025 in Chicago, IL.
Read More
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
About Y-mAbs Therapeutics, Inc. (YMAB)
- IPO Date 2018-09-21
- Website https://www.ymabs.com
- Industry Biotechnology
- CEO Michael Rossi
- Employees 104